ライフサイエンスコーパス: Novartis

1 been optimized to clinical candidates by GNF/Novartis.

2 g Foundation, Roche Diagnostics, Pfizer, and Novartis.

3 art Foundation, UK Medical Research Council, Novartis.

4 fficacy >70%) in a large siRNA data set from Novartis.

5 mithKline) and 5-HT type 4 agonist (Zelnorm, Novartis, AB) drugs on the dynamics of bolus progression

6 ith or without MF59 (registered trademark of Novartis AG) adjuvant (an oil-in-water emulsion).

7 s received the H1N1 vaccine (15-microg dose; Novartis), and antibody titers at baseline and after imm

8 ions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepracor.

9 ions from AstraZeneca, Boehringer Ingelheim, Novartis, and Sepracor; GlaxoSmithKline; Centers for Med

10 ly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor

11 Although imatinib mesylate (STI571, Gleevec, Novartis, Basal, Switzerland) produces high rates of com

12 in-1-yl]phenyl} propanenitrile (NVP-BEZ235) (Novartis, Basel Switzerland), a dual phosphatidylinosito

13 successfully with a targeted drug, imatinib (Novartis, Basel).

14 antibodies (IL-2RAs): basiliximab (Simulect; Novartis, Basel, Switzerland) and daclizumab (Zenapax; R

15 oup C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target

16 nhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable effic

17 transplant recipients receiving CsA (Neoral; Novartis, Basel, Switzerland).

18 eutic targets of imatinib mesylate (Gleevec; Novartis, Basel, Switzerland).

19 with higher selectivity as recently shown by Novartis but that there is little compelling reason to e

20 complex, LCZ696, developed by scientists at Novartis, combines an angiotensin receptor blocker with

21 Comparing the CHEMBL results to Novartis data, we find that significant transformation e

22 th the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels.

23 sel, Switzerland), and cyclosporine (Neoral, Novartis, East Hanover, NJ).

24 asmin (Jetrea, Thrombogenics Inc, USA, Alcon/Novartis EU).

25 e to pollen from a Bt corn hybrid containing Novartis event 176 on two species of Lepidoptera, black

26 paring the observed RPE gene profiles to the Novartis expression database (SymAtlas) of 78 tissues.

27 not inferior to deferoxamine (DFO; Desferal, Novartis) for the removal of cardiac iron in beta-thalas

28 An X-ray-based fragment screen of Novartis' fragment collection resulted in the identifica

29 ith the HDAC inhibitor LBH589 (Panobinostat, Novartis, Germany); levels of proliferation, apoptosis,

30 More recently, GNF/Novartis, GSK, and others have employed the same approac

31 -4-ylamino]-N-met hylbenzamide, TAE226) from Novartis, Inc.

32 KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synth

33 leagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to deferoxamine (DFO; Desferal

34 rmany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisatio

35 rmany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisatio

36 randomized to receive either the IMN Impact (Novartis Nutrition), an enteral feed supplemented with a

37 ependent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respe

38 Two 30-mug doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin) were admini

39 , Switzerland) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular

40 We tested the effect of everolimus (RAD, Novartis Pharma AG, Basel, Switzerland) on human PTLD-de

41 In contrast to our report on Novartis Pharma APP23 Tg mice, which maintain high level

42 of AML were treated with PSC 833 (Valspodar; Novartis Pharmaceutical Corporation, East Hanover, NJ),

43 Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic ac

44 Novartis Pharmaceuticals and Pfizer Inc.

45 medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.

46 inhibitor STI571 (formerly called CGP57148B, Novartis Pharmaceuticals) inhibits BCR/ABL, TEL/ABL, and

47 ; CT1418 (Celltech Therapeutics); CGS27023A (Novartis Pharmaceuticals); and RO31-9790 (Roche), with I

48 Novartis Pharmaceuticals, AirPROM project, and the UK Na

49 AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent

50 tis Pharmaceuticals, Hanover, NJ) (Zortress; Novartis Pharmaceuticals, Basel, Switzerland) is intende

51 r, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly

52 herapy, such as the use of STI-571 (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatmen

53 xample, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown

54 of rapamycin inhibitor everolimus (Certican; Novartis Pharmaceuticals, Hanover, NJ) (Zortress; Novart

55 Novartis Pharmaceuticals, the Indiana University Simon C

56 Primary Funding Source: Genentech and Novartis Pharmaceuticals.

57 newer formulations of cyclosporine, Neoral (Novartis Pharmaceuticals; Basle, Switzerland), and other

58 Medical Research Council, Novartis, Renal Association, Kidney Research UK.

59 In this issue, a team at Novartis reports on the identification of the first dire

60 from the Roche and Genomic Institute of the Novartis Research Foundation SNP databases.

61 Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Council (Lond

62 ancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIH

63 Medical Research Council (London, UK), Novartis, Schering Health Care, Chugai, Pharmion, Celgen

64 ), with unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgen

65 ite in EED discovered by in-house screening, Novartis scientists have now produced a compound that sh

66 Company-sponsored (Genentech or Novartis) studies in DME completed as of December 31, 20

67 for these domains as well as integrated the Novartis SymAtlas2 dataset for both human and mouse whic

68 ciety of Great Britain and Northern Ireland, Novartis, UK National Institute for Health Research (NIH

69 kinase inhibitor imatinib mesylate (Gleevec, Novartis) ultimately led to the discovery of the FIP1L1-

70 Novartis, United States National Cancer Institute, Inter

71 Novartis Vaccines and Diagnostics division (now part of

72 Novartis Vaccines and Diagnostics division, now part of

73 m and the oil-in-water-based emulsions MF59 (Novartis Vaccines and Diagnostics), AS03 and AS04 (Glaxo

74 MF59-adjuvanted trivalent influenza vaccine (Novartis Vaccines and Diagnostics, Siena, Italy) has bee

75 ine (serotypes Ia, Ib, and III, with CRM197 [Novartis Vaccines, Siena, Italy]) intramuscularly at 24-

76 a novel synthetic Smo inhibitor, NVP-LDE225 (Novartis), which decreased MM cell viability by inducing

77 ia drug STI571 [imatinib mesylate (Gleevec); Novartis], which potently and selectively blocks Abl kin